Clinical trial
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
NCT01966419 is registered in ClinicalTrials.gov with Ocera Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
- Lead sponsor
- Ocera Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 7, 2014
- Completion date
- December 29, 2016
- Enrollment
- 231 (actual)
- Sites
- 131
Conditions
As the registry lists them; a condition with its own page is linked.
acute episode of overt hepatic encephalopathy, hepatic encephalopathy